| 6.34 0.21 (3.43%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.63 | 1-year : | 13.26 |
| Resists | First : | 9.1 | Second : | 11.35 |
| Pivot price | 6.49 |
|||
| Supports | First : | 5.45 | Second : | 4.53 |
| MAs | MA(5) : | 6.42 |
MA(20) : | 6.76 |
| MA(100) : | 9.02 |
MA(250) : | 10.04 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 38.6 |
D(3) : | 39 |
| RSI | RSI(14): 40.4 |
|||
| 52-week | High : | 16.19 | Low : | 5.45 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RGNX ] has closed above bottom band by 40.5%. Bollinger Bands are 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.48 - 6.51 | 6.51 - 6.53 |
| Low: | 6.01 - 6.04 | 6.04 - 6.06 |
| Close: | 6.29 - 6.34 | 6.34 - 6.38 |
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Wed, 20 May 2026
Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway - Yahoo Finance
Thu, 14 May 2026
REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 - PR Newswire
Thu, 14 May 2026
Regenxbio down on trial data for Duchenne drug (RGNX:NASDAQ) - Seeking Alpha
Thu, 14 May 2026
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights - PR Newswire
Thu, 07 May 2026
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 4.31e+007 (%) |
| Held by Institutions | 7.7 (%) |
| Shares Short | 6,940 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.4117e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 303.9 % |
| Return on Equity (ttm) | -38.6 % |
| Qtrly Rev. Growth | 8.782e+007 % |
| Gross Profit (p.s.) | -82.86 |
| Sales Per Share | -175.39 |
| EBITDA (p.s.) | -1.54161e+008 |
| Qtrly Earnings Growth | -5.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -234 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 17.31 |
| Dividend | 0 |
| Forward Dividend | 7.14e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|